Iodeto De Sódio [i 131] T Curium Netherlands (Sodium Iodide (131i))

After oral ingestion, Sodium Iodide I-131 is absorbed into the bloodstream and actively transported into thyroid cells by the sodium‑iodide symporter. Inside the gland, the isotope emits beta particles that cause localized radiation damage, leading to cell death, while gamma emissions enable imaging of iodine uptake.

The specific activity and amount of Iodeto De Sódio are determined by the prescribing physician based on the patient’s diagnosis, thyroid size, and prior treatments. Dosing is individualized and calculated in megabecquerels (MBq) or millicuries (mCi) to achieve the therapeutic goal while minimizing exposure.

Radioactive iodine is generally contraindicated in pregnancy because it can cross the placenta and affect the fetal thyroid. Breastfeeding mothers are advised to discontinue nursing for a period recommended by the treating physician, as iodine can be secreted in breast milk and affect the infant’s thyroid function.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Compared with antithyroid drugs, radioactive iodine offers a definitive, single‑administration approach that can permanently reduce thyroid activity. Unlike surgical removal, it is non‑invasive and avoids operative risks. However, it may lead to hypothyroidism requiring lifelong hormone replacement, a consideration when choosing therapy.

Iodeto De Sódio should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and handle it according to standard radiation safety guidelines to avoid contamination.

The product is taken orally, usually as a single dose in capsule or liquid form, under the supervision of a qualified physician. Patients may be instructed to fast before and after administration and to follow specific radiation safety precautions for a short period after dosing.

Serious risks include bone marrow suppression, severe radiation thyroiditis, secondary malignancies such as leukemia, and rare pulmonary fibrosis. Patients should be monitored for blood count changes, signs of excessive neck swelling, and any unexpected systemic symptoms following treatment.

Individuals who are pregnant, nursing, or have uncontrolled severe renal impairment should avoid this medication unless the benefits clearly outweigh the risks. Patients with known hypersensitivity to iodine or previous severe reactions to radioactive iodine therapy should also be excluded.